Journal of Drug Assessment

Journal of Drug Assessment is published by Taylor & Francis Group. By OpenAlex counts of its recent articles, its largest topics are Pharmacy and Medical Practices, Pharmaceutical Practices and Patient Outcomes and Medication Adherence and Compliance, together about 35.8% of its articles. (generated from OpenAlex topic counts and CAS ranking data)

This journal has ceased (2023). The Journal of Drug Assessment is an open access journal that publishes study types on a range of drug therapeutics of interest to the clinical medicine and research communities. The journal aims to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The journal’s objective is to help facilitate improvements in patient health by facilitating a collaborative and honest approach to publication. The journal welcomes smaller studies, preliminary and pilot studies, results from trials that have not met their endpoints and studies with confirmatory findings from Phase I–Phase IV trials. It also welcomes review articles and meta- The journal’s scope — combined with the transparent and rigorous peer review process — make certain that papers are accepted based on their scientific merit (i.e., technically sound, well-written, comprehensive reports), not on the novelty or impact of the results. In addition, the rapid publication timeline allows for online publication within 7-9 weeks of submission, whilst always ensuring total transparency of the peer-review process and disclosure of financial and other relevant relationships for all submitted manuscripts. The Journal of Drug Assessment publishes: Smaller and lower-impact studies and early trial data Null or negative study results in addition to incomplete, inconclusive or controversial results Confirmatory studies and updates to previous research Case studies in clinical practice, involving new and existing drugs Reviews on new and existing drugs, novel study designs, research and pharmacoeconomic outcomes Full-length original articles and meta-analyses that report the results of Phase I–IV studies on pharmaceutical products and medical devices in all drug classes, therapeutic areas and disease states (including approved and unapproved products, therapeutic diagnostic/theranostic products and over-the-counter medicines) Brief research reports that meet the above criteria and have the same elements as a full-length paper, but are shorter, and provide more concise information in each element, with fewer illustrations Editorials commenting on new developments in pharmaceutical regulatory affairs, new policies, health outcomes and drug manufacturing, and controversial clinical and preclinical findings Letters to the Editor as correspondence to the Editor on previously published work The journal operates a single-blind peer review p

From the journal's Aims & Scope

Research area (LetPub): PHARMACOLOGY & PHARMACY

CAS Journal Ranking

Database indexing

Indexed in: no record yet.

Early warning / risk: Marked as ceased in ESCI on 21 February 2024. CAS Early Warning Journal List: not listed in any of 6 editions.LetPub

Indexing the journal's website claims

MEDLINEPMCEmbaseCINAHLPublisher website

As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor (publisher) 2022

2.4Publisher website · 2026-11-01

5-year impact factor (publisher) 2022

3Publisher website · 2026-11-01

h-index

26OpenAlex · 2026-11-01

i10-index

62OpenAlex · 2026-11-01

2-year mean citedness

0OpenAlex · 2026-11-01

Share of gold OA articles

100%LetPub · 2026-11-01

Volume

Articles per year

3LetPub · 2026-11-01

Downloads per year (publisher)

49,000Publisher website · 2026-11-01

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Average review time (community reports)

about 8 weeksLetPub · 2026-11-01

Acceptance rate (publisher)

29%Publisher website · 2026-11-01

Peer review

Blind peer reviewLetPub

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Taylor & Francis Group

Country or region

United Kingdom

Language

English

ISSN

1369-9474

Electronic ISSN

2155-6660

Latest issue on the website

Volume 12, Issue 1 (2023)

Official links

• Journal homepage ↗LetPub
• Author guidelines ↗LetPub
• Aims & Scope ↗LetPub
• Special issues ↗Publisher website
• Peer review process ↗LetPub
• Editorial board ↗LetPub